8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Clinical Stage Transitions in Persons Aged 12 to 25 Years Presenting to Early Intervention Mental Health Services With Anxiety, Mood, and Psychotic Disorders

      research-article
      , PhD 1 , , , MD, FRANZCP 1 , 2 , , PhD 1 , , PhD 1 , , PhD 1 , 3 , , PhD 4 , , PGDipAppPsy 1 , , MCouns 1 , , BLaS (Stats) 1 , , PhD 1 , , PhD, FRCPsych 5 , , MD, PhD, FRCP, FRANZCP 6 , 7 , , MD, FRANZCP, FASSA, FAHMS 1
      JAMA Psychiatry
      American Medical Association

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What demographic and clinical factors are associated with transition from early (subthreshold) to full-threshold major persistent or recurrent psychiatric disorders?

          Findings

          This longitudinal cohort study of persons aged 12 to 25 years who presented to early intervention services found significant and ongoing risk of transition to major anxiety, mood, psychotic, or comorbid disorders. Poorer social function, psychotic-like experiences, manic-like experiences, and circadian disturbance were associated with illness progression.

          Meaning

          A clinical staging model for specific youth services may support the efficient allocation of appropriate care to young people and support the evidence-based planning of relevant early intervention and secondary prevention strategies.

          Abstract

          This Australian longitudinal cohort study follows up 2254 individuals aged 12 to 25 years who obtained care from early-intervention mental health services to compare progression of disorder based on demographic features and clinical stage at presentation.

          Abstract

          Importance

          The large contribution of psychiatric disorders to premature death and persistent disability among young people means that earlier identification and enhanced long-term care for those who are most at risk of developing life-threatening or chronic disorders is critical. Clinical staging as an adjunct to diagnosis to address emerging psychiatric disorders has been proposed for young people presenting for care; however, the longer-term utility of this system has not been established.

          Objectives

          To determine the rates of transition from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders and to identify the demographic and clinical characteristics that are associated with the time course of these transitions.

          Design, Setting, and Participants

          A longitudinal, observational study of 2254 persons aged 12 to 25 years who obtained mental health care at 2 early intervention mental health services in Sydney, Australia, and were recruited to a research register between June 18, 2008, and July 24, 2018 (the Brain and Mind Centre Optymise Cohort).

          Main Outcomes and Measures

          The primary outcome of this study was transition from earlier to later clinical stages. A multistate Markov model was used to examine demographic (ie, age, sex, engagement in education, employment, or both) and clinical (ie, social and occupational function, clinical presentation, personal history of mental illness, physical health comorbidities, treatment use, self-harm, suicidal thoughts and behaviors) factors associated with these transitions.

          Results

          Of the 2254 individuals included in the study, mean (SD) age at baseline was 18.18 (3.33) years and 1330 (59.0%) were female. Data on race/ethnicity were not available. Median (interquartile range) follow-up was 14 (5-33) months. Of 685 participants at stage 1a (nonspecific symptoms), 253 (36.9%) transitioned to stage 1b (attenuated syndromes). Transition was associated with lower social functioning (hazard ratio [HR], 0.77; 95% CI, 0.66-0.90), engagement with education, employment, or both (HR, 0.47; 95% CI, 0.25-0.91), manic-like experiences (HR, 2.12; 95% CI, 1.19-3.78), psychotic-like experiences (HR, 2.13; 95% CI, 1.38-3.28), self-harm (HR, 1.42; 95% CI, 1.01-1.99), and older age (HR, 1.27; 95% CI, 1.11-1.45). Of 1370 stage 1b participants, 176 (12.8%) transitioned to stage 2 (full-threshold) disorders. Transition was associated with psychotic-like experiences (HR, 2.31; 95% CI, 1.65-3.23), circadian disturbance (HR, 1.66; 95% CI, 1.17-2.35), psychiatric medication (HR, 1.43; 95% CI, 1.03-1.99), childhood psychiatric disorder (HR, 1.62; 95% CI, 1.03-2.54), and older age (HR, 1.24; 95% CI, 1.05-1.45).

          Conclusions and Relevance

          Differential rates of progression from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders were observed in young persons who presented for care at various stages. Understanding the rate and factors associated with transition assists planning of stage-specific clinical interventions and secondary prevention trials.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort.

          If most adults with mental disorders are found to have a juvenile psychiatric history, this would shift etiologic research and prevention policy to focus more on childhood mental disorders. Our prospective longitudinal study followed up a representative birth cohort (N = 1037). We made psychiatric diagnoses according to DSM criteria at 11, 13, 15, 18, 21, and 26 years of age. Adult disorders were defined in the following 3 ways: (1) cases diagnosed using a standardized diagnostic interview, (2) the subset using treatment, and (3) the subset receiving intensive mental health services. Follow-back analyses ascertained the proportion of adult cases who had juvenile diagnoses and the types of juvenile diagnoses they had. Among adult cases defined via the Diagnostic Interview Schedule, 73.9% had received a diagnosis before 18 years of age and 50.0% before 15 years of age. Among treatment-using cases, 76.5% received a diagnosis before 18 years of age and 57.5% before 15 years of age. Among cases receiving intensive mental health services, 77.9% received a diagnosis before 18 years of age and 60.3% before 15 years of age. Adult disorders were generally preceded by their juvenile counterparts (eg, adult anxiety was preceded by juvenile anxiety), but also by different disorders. Specifically, adult anxiety and schizophreniform disorders were preceded by a broad array of juvenile disorders. For all adult disorders, 25% to 60% of cases had a history of conduct and/or oppositional defiant disorder. Most adult disorders should be reframed as extensions of juvenile disorders. In particular, juvenile conduct disorder is a priority prevention target for reducing psychiatric disorder in the adult population.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions.

            Diagnosis in psychiatry increasingly struggles to fulfil its key purposes, namely, to guide treatment and to predict outcome. The clinical staging model, widely used in clinical medicine yet virtually ignored in psychiatry, is proposed as a more refined form of diagnosis which could restore the utility of diagnosis, promote early intervention and also make more sense of the confusing array of biological research findings in psychiatry by organizing data into a coherent clinicopathological framework. A selective review of key papers in clinical medicine and psychiatry which describe clinical and clinicopathological staging, and a range of related issues. Clinical staging has immediate potential to improve the logic and timing of interventions in psychiatry just as it does in many complex and potentially serious medical disorders. Interventions could be evaluated in terms of their ability to prevent or delay progression from earlier to later stages of disorder, and they could be selected on clear-cut risk/benefit criteria. Biological variables and a range of candidate risk factors could be studied within and across stages, and their role, specificity and centrality in risk, onset and progression of disorder could be greatly clarified. A clinicopathological framework could be progressively constructed. Clinical staging with a restructure across and within diagnostic boundaries with the explicit operationalization of criteria for extent and progression of disorder should be actively explored in psychiatry as a heuristic strategy for the development and evaluation of earlier, safer, and more effective clinical interventions, and for clarifying the biological basis of psychiatric disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity--implications for diagnosis and ultra-high risk research.

              It is commonly assumed that there are clear lines of demarcation between anxiety and depressive disorders on the one hand and psychosis on the other. Recent evidence, however, suggests that this principle may be in need of updating. Depressive and/or anxiety disorders, with no previous history of psychotic disorder, were examined for the presence of psychotic symptoms in a representative community sample of adolescents and young adults (Early Developmental Stages of Psychopathology study; n = 3021). Associations and consequences of psychotic symptomatology in the course of these disorders were examined in terms of demographic distribution, illness severity, onset of service use, and risk factors. Around 27% of those with disorders of anxiety and depression displayed one or more psychotic symptoms, vs 14% in those without these disorders (OR 2.23, 95% CI 1.89-2.66, P < .001). Presence as compared with nonpresence of psychotic symptomatology was associated with younger age (P < .0001), male sex (P < .0058), and poorer illness course (P < .0002). In addition, there was greater persistence of schizotypal (P < .0001) and negative symptoms (P < .0170), more observable illness behavior (P < .0001), greater likelihood of service use (P < .0069), as well as more evidence of familial liability for mental illness (P < .0100), exposure to trauma (P < .0150), recent and more distant life events (P < .0006-.0244), cannabis use (P < .0009), and any drug use (P < .0008). Copresence of psychotic symptomatology in disorders of anxiety and depression is common and a functionally and etiologically highly relevant feature, reinforcing the view that psychopathology is represented by a network or overlapping and reciprocally impacting dimensional liabilities.
                Bookmark

                Author and article information

                Journal
                JAMA Psychiatry
                JAMA Psychiatry
                JAMA Psychiatry
                JAMA Psychiatry
                American Medical Association
                2168-622X
                2168-6238
                28 August 2019
                November 2019
                28 August 2020
                : 76
                : 11
                : 1167-1175
                Affiliations
                [1 ]Youth Mental Health Team, Brain and Mind Centre, University of Sydney, New South Wales, Australia
                [2 ]The University of Notre Dame, St Vincent’s and Mater Clinical School, Sydney, New South Wales, Australia
                [3 ]Sunshine Coast Mind and Neuroscience Thompson Institute, University of the Sunshine Coast, Birtinya, Queensland, Australia
                [4 ]Sydney Informatics Hub, University of Sydney, New South Wales, Australia
                [5 ]Academic Psychiatry, Institute of Neuroscience, Newcastle University, United Kingdom
                [6 ]Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia
                [7 ]Centre for Youth Mental Health, University of Melbourne, Victoria, Australia
                Author notes
                Article Information
                Accepted for Publication: June 3, 2019.
                Corresponding Author: Frank Iorfino, PhD, Youth Mental Health Team, Brain and Mind Centre, University of Sydney, 94 Mallet St Camperdown, Sydney, New South Wales, Australia 2050 ( frank.iorfino@ 123456sydney.edu.au ).
                Published Online: August 28, 2019. doi:10.1001/jamapsychiatry.2019.2360
                Author Contributions : Drs Hickie and Iorfino had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs E. M. Scott and Iorfino are joint first authors.
                Concept and design: Iorfino, E. M. Scott, Carpenter, Cross, Hermens, J. Scott, McGorry, Hickie.
                Acquisition, analysis, or interpretation of data: Iorfino, Carpenter, Cross, Hermens, Killedar, Nichles, Zmicerevska, White, Guastella, J. Scott, Hickie.
                Drafting of the manuscript: Iorfino, Hermens, Killedar, J. Scott.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Iorfino, Killedar, J. Scott.
                Obtained funding: Hickie.
                Administrative, technical, or material support: E. M. Scott, Carpenter, Zmicerevska, White, Guastella, Hickie.
                Supervision: E. M. Scott, Cross, Hermens, Guastella, J. Scott, Hickie.
                Conflict of Interest Disclosures: Dr E. M. Scott is medical director, Young Adult Mental Health Unit, St Vincent’s Hospital Darlinghurst; discipline leader of Adult Mental Health, School of Medicine, University of Notre Dame; Research Affiliate, The University of Sydney; and Consultant Psychiatrist. She has received honoraria from Laboratoires Servier and Eli Lilly and Company for presenting educational seminars related to the clinical management of depressive disorders and has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the national coordinator of an antidepressant trial sponsored by Laboratoires Servier. Dr J. Scott is a visiting professor at Diderot University, the Norwegian University of Science and Technology, Swinburne University of Technology, and The University of Sydney and a Science Without Borders fellow (Brazil). She has received grant funding from the UK Medical Research Council and from the UK Research for Patient Benefit program. Dr Hickie was an inaugural Commissioner on Australia’s National Mental Health Commission (2012-18). He is the co-director, Health and Policy at the Brain and Mind Centre (BMC), University of Sydney. The BMC operates an early-intervention youth service at Camperdown under contract to headspace, National Youth Mental Health Foundation Ltd. Dr Hickie has previously led community-based and pharmaceutical industry–supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca) projects focused on the identification and better management of anxiety and depression. He was a member of the Medical Advisory Panel for Medibank Private until October 2017, a board member of Psychosis Australia Trust, and a member of Veterans Mental Health Clinical Reference group. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of Sydney (45% equity) and PricewaterhouseCoopers ([PwC] Australia; 45% equity) to deliver the $30 million Australian Government-funded Project Synergy (2017-2020; a 3-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. No other conflicts were reported.
                Funding/Support: This work was partially supported by grants from the National Health & Medical Research Council Centre of Research Excellence grant 1061043, and Australia Fellowship 511921 (both, Dr Hickie).
                Role of the Funder/Sponsor: The funders had no input into the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: We would like to thank all the young people who have participated in this study and all the staff in the Youth Mental Health Team at the Brain and Mind Centre, past and present, who have contributed to this work.
                Article
                PMC6714017 PMC6714017 6714017 yoi190055
                10.1001/jamapsychiatry.2019.2360
                6714017
                31461129
                e1c7e280-3d5e-478b-8fce-1c068d196a2b
                Copyright 2019 American Medical Association. All Rights Reserved.
                History
                : 27 February 2019
                : 3 June 2019
                Categories
                Research
                Research
                Original Investigation
                Featured
                Online First
                Comments

                Comments

                Comment on this article